Ocular Therapeutix Inc. - notizie pubblicate 197 - letture 2.120
OCULAR THERAPEUTIX INC.
Ocular Therapeutix™ Provides Fourth Quarter and Year-End 2022 Results and Corporate Update - Form 8-K
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer ocular therapeutix i ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix™ to Present at Cowen’s 43rd Annual Healthcare Conference
Pdf version bedford, mass., feb. 28, 2023 (globe newswire) -- ocular therapeutix, inc. (nasdaq:ocul), a biopharmaceutical company focused on the formulation, development, and comme ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2022 Financial Results
Pdf version bedford, mass., feb. 21, 2023 (globe newswire) -- ocular therapeutix, inc. (nasdaq:ocul), a biopharmaceutical company focused on the formulation, development, and comme ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix™ Announces Interim 10-month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer ocular therapeutix i ...
OCULAR THERAPEUTIX INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
OCULAR THERAPEUTIX INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
OCULAR THERAPEUTIX INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
OCULAR THERAPEUTIX INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
OCULAR THERAPEUTIX INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
OCULAR THERAPEUTIX INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
OCULAR THERAPEUTIX INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix™ Provides 2022 Year End Corporate Update and Reviews Expected 2023 Milestones
Pdf version dextenza® net product revenue in the fourth quarter of 2022 is estimated to be $13.6 million, growing approximately 14% over previous quarter and approximately 11% ove ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix™ Provides 2022 Year End Corporate Update and Reviews Expected 2023 Milestones - Form 8-K
Ocular therapeutix™ provides 2022 year end corporate update and reviews expected 2023 milestones dextenza® net product revenue in the fourth quarter of 2022 is estimated to be $ ...
OCULAR THERAPEUTIX INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences
Pdf version bedford, mass.--(business wire)--nov. 8, 2022-- ocular therapeutix, inc. (nasdaq:ocul), a biopharmaceutical company focused on the formulation, development, and commerc ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti